PMID: 558038Apr 22, 1977Paper

Amphetamine-haloperidol interactions in rat striatum: failure to correlate behavioral effects with dopaminergic and cholinergic dynamics

Brain Research
R KuczenskiN Leith

Abstract

Previous reports have suggested that the hyperactivity and stereotypy produced by amphetamine (AMP) and the catalepsy produced by haloperidol (HAL) are mediated by striatal dopaminergic mechanisms. In the present study, we have measured the behavioral effects of AMP and HAL, and their effects on striatal dopaminergic function, using both an index of pre-synaptic activity (synaptosomal dopamine (DA) synthesis) and a parameter which we suggest will reflect post-synaptic dopaminergic function (sodium-dependent, high affinity choline uptake). Administration of 2 mg/kg AMP produces hyperactivity and causes a decrease in DA biosynthesis, both of which are blocked by 0.75 mg/kg HAL. AMP (5 mg/kg) produces stereotypy, further decreases DA biosynthesis and causes a decrease in choline uptake, consistent with stimulation of DA receptors. However, while pretreatment with 3 mg/kg HAL completely blocked the stereotypy induced by 5 mg/kg AMP it failed to reverse the effects of this dose on either DA biosynthesis or choline uptake. These data suggest that either 5 mg/kg AMP affects straital dopaminergic and cholinergic parameters by a mechanism independent of HAL sensitive receptors, or the stereotypy produced by high doses of AMP are not rel...Continue Reading

References

Aug 1, 1975·European Journal of Pharmacology·B H Westerink, J Korf
Nov 7, 1975·Science·P M GrovesG V Rebec
Feb 1, 1975·European Journal of Pharmacology·R Kuczenski, D S Segal
Sep 1, 1973·The Journal of Pharmacy and Pharmacology·J E Harris, R J Baldessarini
Jan 1, 1974·The Journal of Pharmacy and Pharmacology·B Costall, R J Naylor
Feb 1, 1974·European Journal of Pharmacology·B Costall, R J Naylor
Mar 1, 1969·Proceedings of the National Academy of Sciences of the United States of America·M J BessonJ Glowinski
Feb 1, 1974·European Journal of Pharmacology·B Costall, R J Naylor
Jun 1, 1974·European Journal of Pharmacology·B Costall, R J Naylor
Dec 1, 1974·European Journal of Pharmacology·M T Price, H C Fibiger
Feb 1, 1970·British Journal of Pharmacology·R O'KeeffeM Vogt
Oct 1, 1971·Proceedings of the National Academy of Sciences of the United States of America·A S Horn, S H Snyder
Jan 1, 1970·European Journal of Pharmacology·N E AndénU Ungerstedt
Sep 1, 1967·European Journal of Pharmacology·H CorrodiT Hökfelt
Jan 1, 1963·Acta Pharmacologica Et Toxicologica·A CARLSSON, M LINDQVIST

❮ Previous
Next ❯

Citations

Jul 1, 1981·Neuroscience and Behavioral Physiology·S I Bazhenova, N B Saul'skaya
Jun 1, 1988·Biological Psychiatry·S P MahadikS E Karpiak
Oct 1, 1979·European Journal of Pharmacology·C BianchiL Beani
Feb 1, 1984·Pharmacology, Biochemistry, and Behavior·Y Hiraga, T Iwasaki
Oct 28, 1977·Science·D S SegalR Guillemin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here